{"ticker": {"uuid": "36f42c2f-1d8c-4b2b-92b4-62c8907921b4", "symbol": "ARVN", "name": "Arvinas Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Trading the Move, Not the Narrative: (ARVN) Edition", "summary": "This article analyzes Arvinas Inc. (NASDAQ: ARVN) using AI models to provide trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but long-term strength, with specific entry, target, and stop-loss levels for position trad", "url": "https://news.stocktradersdaily.com/news_release/39/Trading_the_Move,_Not_the_Narrative:_ARVN_Edition_071726053402_1784280842.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T05:34:06", "published_display": "17 Jul 2026 05:34", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arvinas (ARVN) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AJBVV95cUxQX2R4b2NwclZnek9PbWp0bV8wYzhmbTd6Ym9CZTFnMVZiU1ZEREJLWEtNTEdYdmtfamJrVkphQS1QZjZrNE5ESlpNS0hmd2xjSHNGUkZhMDBiN3QtYjNvOG1QQWZZQ1NiNDVTVjBXYk9YbzBzWUZFdHIzQjliU0tYbHQ0QlBOMlJQcU1nRW9wdnVNUGFGcjRnQ1NoSGlEYnU3U0MyLV9ZWGcwdWs1UElLRVdadTJRbmV5UGp4NTd3bW1ZaHhDWjlDR2p4cEZfY0cySzNTS0xUMUR1aW1pVS1QcXhxdjdiSVpkaTlUZGJ3Q29YWUtfSEt3WUNxNThqeExXbWNhd3FRWHIwRHBkSE1SWGdkUmVud1V5T193WUU4T0FpSXBlZ0t5dVc5b1dXckpoaVNOck9oZ2Q2RXB5cDBFZGRORmFpWThLLW9lZlRjNGhpeG54ajdIZ0xLNDE5eU9Q?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T20:32:37+00:00", "published_display": "13 Jul 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ARVN News | ARVINAS INC (NASDAQ:ARVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5wNTZ4VGhRWXk2TTBaQUZvVk84YlBWcHFEWU5QeXNuWmFhcmprREcwSzN1QzNjWmMzeGFOOG91NG1seWVFdlVoR1RBTTVOT09QVnVTbW9YazNJWkE?oc=5", "source_name": "ChartMill", "published_at": "2026-07-10T21:48:26+00:00", "published_display": "10 Jul 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares", "summary": "Morgan Stanley Smith Barney LLC has filed a Form 144 notice indicating its intent to sell 24,000 shares of common stock in Arvinas, Inc. (ARVN). These sales are tied to restricted stock vesting under a registered plan, with specific vesting lots scheduled for March 2025, February", "url": "https://www.stocktitan.net/sec-filings/ARVN/144-arvinas-inc-sec-filing-1af59be62526.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:41:52", "published_display": "09 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN - Arvinas Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview and recent SEC filing information for Arvinas Inc. (ARVN). It covers various financial metrics including market capitalization, sales, income, profitability ratios, insider and institutional ownership, stock performance, and ana", "url": "https://finviz.com/stock?t=ARVN&p=d&b=2&r=m3&ty=lf&page=9", "source_name": "Finviz", "published_at": "2026-07-03T10:10:15", "published_display": "03 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) director receives RSU and stock option grants in equity award", "summary": "Arvinas (ARVN) director Leslie V. Norwalk received routine equity compensation through a grant of 15,527 restricted stock units (RSUs) and an option to purchase 22,714 shares of common stock at $8.05 per share. These awards, granted on June 24, 2026, are not open-market trades an", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-5e63b48ea57d.html", "source_name": "Stock Titan", "published_at": "2026-06-27T08:10:24", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arvinas Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Arvinas Inc. on June 26. The content includes market data for various indices, currencies, and commodities, reflecting market performance. It also lists trending stocks and popular articles related to financial ne", "url": "https://za.investing.com/news/stock-market-news/form-4-arvinas-inc-for-26-june-93CH-4346330", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T22:26:00", "published_display": "26 Jun 2026 22:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options", "summary": "Arvinas (ARVN) director Briggs Morrison was granted 15,527 restricted stock units (RSUs) and 22,714 stock options with an exercise price of $8.05 per share. These equity awards, reported on a Form 4 filing, are subject to vesting criteria tied to continued service and the company", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-66a021c4281a.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:41:20", "published_display": "26 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Linda Bain receives RSUs and stock options at Arvinas (ARVN)", "summary": "Arvinas, Inc. director Linda Bain was granted 15,527 restricted stock units (RSUs) and stock options for 22,714 shares at an exercise price of $8.05 per share. Both the RSUs and options vest fully on the earlier of June 24, 2027, or immediately before the first annual stockholder", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-497040da74a1.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:41:20", "published_display": "26 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] ARVINAS, INC. Insider Trading Activity", "summary": "Edward M. Kennedy Jr., a director at ARVINAS, INC. (ARVN), received new equity awards comprising 15,527 restricted stock units (RSUs) and an option to purchase 22,714 shares at an exercise price of $8.05 per share. These awards were granted on June 24, 2026, and are set to vest f", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-bf718e269e1c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:41:20", "published_display": "26 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) director receives new RSU and stock option awards", "summary": "Arvinas, Inc. director Everett Cunningham was granted 15,527 restricted stock units (RSUs) and a stock option for 22,714 shares at an exercise price of $8.05, according to a June 24, 2026 filing. Both awards are set to vest on the earlier of June 24, 2027, or immediately before t", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-5f8750cdc6da.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:37:35", "published_display": "26 Jun 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSUNNUjAydlN2ZXJKMXdDZV8taDJZNzMxRUVVbm5fV3RrelNkYXRfazJ2c2JCZWZiQ21BcWh3dFRDd1FwNmxnckw2SlJNYXZ4SlhQWlYzZDZ5RFpERzBpODBENmZiYktfM0FTbklELW9xcEpmcHFKZ1RvZ2s5X3p6LW1GTlV0M1RqeUNYanlZS0VaUGZ1SjZjX1pxM0JTNlVvZHk3RERyMjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN)", "summary": "This article provides key financial actuals and estimates for Arvinas, Inc. (NASDAQ:ARVN), including its current stock price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent earnings, revenue, net income, and upcoming earnings repor", "url": "https://www.tradingview.com/symbols/NASDAQ-ARVN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:20", "published_display": "26 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Inc (ARVN) Institutional Confidence", "summary": "Arvinas Inc (ARVN) has an institutional shareholding score of 7.00, placing it 80th out of 387 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 83.59%, which is a decrease of 50.35% quarter-over-quarter. Bill Nygren | OAKMX is the lar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arvn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-26T04:40:21", "published_display": "26 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor", "summary": "Arvinas, Inc. held its annual meeting on June 24, 2026, where stockholders elected Leslie V. Norwalk, Esq. and Randy Teel, Ph.D. as Class II directors. They also approved, on a non-binding advisory basis, the compensation for named executive officers and ratified Deloitte & Touch", "url": "https://www.stocktitan.net/sec-filings/ARVN/8-k-arvinas-inc-reports-material-event-023a4cb3428e.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:40:08", "published_display": "25 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas CFO Andrew Saik sells $46,473 in company stock", "summary": "Arvinas CFO Andrew Saik sold 5,696 shares of company stock for $46,473 to cover tax withholding obligations related to the vesting of restricted stock units. This was not a discretionary trade. The stock is currently trading below its fair value, despite a recent earnings report ", "url": "https://www.investing.com/news/insider-trading-news/arvinas-cfo-andrew-saik-sells-46473-in-company-stock-93CH-4759239", "source_name": "Investing.com", "published_at": "2026-06-25T20:09:35", "published_display": "25 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arvinas Inc For: 24 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Arvinas Inc (ARVN) dated June 24, 2026. Form 4s disclose transactions by company insiders, but the article provides no specific details about the transactions, only listing the filing and referencing the stock ticker.", "url": "https://ng.investing.com/news/stock-market-news/form-4-arvinas-inc-for-24-june-93CH-2573010", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T19:37:35", "published_display": "25 Jun 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Arvinas, Inc. (ARVN) stock, including analyst price targets, current stock performance, and financial data. It highlights that the stock has a price target of 15.07 USD based on 14 analysts, with a max estimate of 24.00 USD and a min of 6.00 U", "url": "https://www.tradingview.com/symbols/NASDAQ-ARVN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:21", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVINAS (ARVN) CFO auto-sells shares to cover RSU tax withholding", "summary": "ARVINAS, INC.'s Chief Financial Officer, Andrew Saik, automatically sold 5,696 shares of common stock at $8.159 per share to cover tax withholding obligations related to the vesting of his restricted stock units. This was a non-discretionary sale made by the company and not a per", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-a8fa1bc4f627.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:10:13", "published_display": "24 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Arvinas Inc For: 23 June By Investing.com", "summary": "This article from Investing.com reports on Form 144 for Arvinas Inc. filed on June 23rd. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the filing date and company name.", "url": "https://ng.investing.com/news/stock-market-news/form-144-arvinas-inc-for-23-june-93CH-2571125", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T18:11:29", "published_display": "24 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN: All voting items passed at the virtual meeting, with no shareholder questions submitted", "summary": "Arvinas, Inc. (ARVN) held its virtual Annual General Meeting (AGM) where all proposed agenda items were approved by shareholders. These items included director elections, executive compensation, and auditor ratification. No shareholder questions were submitted during the meeting.", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3648079:0-arvn-all-voting-items-passed-at-the-virtual-meeting-with-no-shareholder-questions-submitted/", "source_name": "TradingView", "published_at": "2026-06-24T13:41:25", "published_display": "24 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) to settle 5,846 vested RSU shares on 06/24/2026", "summary": "Arvinas, Inc. (NASDAQ: ARVN) is set to settle 5,846 shares of common stock stemming from vested restricted stock units on June 24, 2026, through Morgan Stanley Smith Barney LLC. The SEC Form 144 filing also notes a previous disposition of 11,139 shares by Andrew Saik on May 11, 2", "url": "https://www.stocktitan.net/sec-filings/ARVN/144-arvinas-inc-sec-filing-50c29b2381fd.html", "source_name": "Stock Titan", "published_at": "2026-06-23T21:40:40", "published_display": "23 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] ARVINAS, INC. Reports Material Event", "summary": "ARVINAS, INC. has reported a material event in an 8-K filing, announcing that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. will depart from the company on July 3, 2026. A separation agreement includes nine months of base salary, health premiums, and accelerated vesting of ce", "url": "https://www.stocktitan.net/sec-filings/ARVN/8-k-arvinas-inc-reports-material-event-e64329957ef4.html", "source_name": "Stock Titan", "published_at": "2026-06-23T05:40:40", "published_display": "23 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas, Inc. $ARVN Stock Holdings Lifted by Armistice Capital LLC", "summary": "Armistice Capital LLC significantly increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 50% in the fourth quarter, now holding 1.8 million shares valued at $21.35 million. While institutional investors are increasing positions, company insiders, including the CFO, recently sold", "url": "https://www.marketbeat.com/instant-alerts/filing-arvinas-inc-arvn-stock-holdings-lifted-by-armistice-capital-llc-2026-06-18/", "source_name": "MarketBeat", "published_at": "2026-06-19T22:09:24", "published_display": "19 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) CSO has shares sold automatically to cover RSU tax withholding", "summary": "Arvinas, Inc.'s Chief Scientific Officer, Angela M. Cacace, automatically sold 2,576 shares of common stock at $7.595 per share. This non-discretionary sale was executed by the issuer to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). ", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-05b684d2b303.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:43:39", "published_display": "18 Jun 2026 19:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment", "summary": "Rigel Pharmaceuticals has secured exclusive global rights to develop and commercialize VEPPANU from Arvinas and Pfizer, following the early termination of the Hart-Scott-Rodino waiting period. This agreement triggered an upfront payment of $70 million, shared by Arvinas and Pfize", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARVN/pressreleases/2525021/rigel-deal-for-veppanu-cleared-arvinas-receives-payment/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T05:40:40", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Arvinas Inc (ARVN) has an earnings forecast score of 7.40, ranking 293 out of 388 in the Biotechnology & Medical Research industry. The average analyst price target for ARVN is $14.00, with 18 analysts predominantly recommending a \"Buy\" trend. The company's expected revenue for t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arvn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:48", "published_display": "17 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Inc (ARVN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of Arvinas Inc's (ARVN) dividend payouts and stock splits, noting that the company has distributed $0.00 in dividends over the past five years. It also indicates that there is no historical data available for stock splits. The content pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arvn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:36", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) insider sells 2,642 shares; May sale of 9,657 noted", "summary": "An insider at Arvinas (NASDAQ: ARVN) sold 2,642 shares on June 17, 2026, stemming from vested restricted stock units. This Form 144 SEC filing also notes a previous sale of 9,657 common shares by Angela Cacace on May 11, 2026, for $95,965.47. The transactions are considered routi", "url": "https://www.stocktitan.net/sec-filings/ARVN/144-arvinas-inc-sec-filing-ab03911b86fb.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:10:23", "published_display": "17 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a", "summary": "An agreement between Arvinas Holding Company LLC and Pfizer, detailed in a U.S. SEC document, outlines potential milestone payments of up to $320 million and a tiered royalty structure for both companies. These payments are phased based on R&D progress, regulatory approvals, and ", "url": "https://www.bitget.com/amp/news/detail/12560605463269", "source_name": "Bitget", "published_at": "2026-06-16T21:40:00", "published_display": "16 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) secures $70M VEPPANU payment and major milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQcUZKWVkyQlZ6emdlVGgybkJDMEdMU0VIWDQ0U2lTdFpLZHBhMm5PTDdhQjJtX2tpeDF2OERaRnJrTnoxS3dCb2hZYzEzcDdXUzFmeDVPWDN4aWdEX0FUTzMzZ1MtLVhLOUNGTEl4YnljQ3pudUZUSE91eXBZYkthMzNIQlJrZ3lFTDFjczR4UmRoMTZPMDQxaGRCQThzTmZtNGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data", "summary": "", "url": "https://finance.yahoo.com/m/09445a3d-4d83-38f8-9d7f-b4d836f150fd/arvinas-sharpens-pipeline.html", "source_name": "MarketBeat", "published_at": "2026-06-05T16:10:37+00:00", "published_display": "05 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Joins The Michael J. Fox Foundation\u2019s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arvinas-joins-michael-j-fox-120000666.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas joins Michael J. Fox effort to develop new Parkinson's therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQQnBZM0p5ZnpQRUVnWlRmdWdxV3FOQ2RZX1hiUndtT3RkVEREVW1QY3Z1SUJDWF9zeFN6ZFRkZzVoN2dvT1lObWpqaVZjajhXSS1aSHhXcUlVRmc5RUdRUlVyV3NHazlPT0dLV3BfU0Z3ZHR5Zkl2SHdNd1JaMEVYbUtZdGZPSjR2Q1RVNmswODgzbUZWOE5teXdtdGw4R3MxcEh4QTVjakFZeHptSWxNTXV3ZlItNnV3NGNybmRQQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas to Present at Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arvinas-present-jefferies-global-healthcare-200100166.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T20:01:00+00:00", "published_display": "29 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies healthcare conference to feature Arvinas fireside chat June 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPZnppbFl4T3NuUkNrckRmUGw5eUREaXkxaEtveDUyWTdOQllvTkcyLUFfdVJHa0RUN1F2WkwySEwzWWVkMllhSlBaY0M5QkwtcjB0WkpUT3o1NjRqZDFMSzk1MjNkXzU3bmp5Z01lZzNJU25Mem5CQmt2dUE1MmlmWGNDa2pMMl9XTm14enBoa0pGWlhVZllCWnpXQTlwdllCTU1HTnFkUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Employees Give Back During Company-wide Impact Day", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arvinas-employees-back-during-company-143000094.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T14:30:00+00:00", "published_display": "18 May 2026 14:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas staff spend a day cooking, cleaning and crafting for patients and kids", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQWk5leXN0UXBoamlsUHA4YmtsaUExYi1iN1JGaGwxSVR4UFBXelhkcGJRY2pQVDlneWZnNktKcVBuWlB5eEx6Z3RhcWYtaFUxcFdLNnVuMGdrV1k0TnB0MFRyVWUyRHFVRkE0ZUt5Y0tHZjBROWhlTXE1TVVNS2E0U0NkZFFPR1d4dG9BYzVpMkc4bFVMMER4RWxGUnBISkcxWTZjSnRGWkZTNWJGZ2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bullish-analysts-just-made-noticeable-134017950.html", "source_name": "Simply Wall St.", "published_at": "2026-05-16T13:40:17+00:00", "published_display": "16 May 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-pharmaceuticals-inks-breast-cancer-203107776.html", "source_name": "Benzinga", "published_at": "2026-05-15T20:31:07+00:00", "published_display": "15 May 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNRkxVR2xZM1lqdGZ2NXh2Qk1VYkwzazNLUEc4TGFVVlhUaU9VTEhyX3didlBnWFBzVVhvcDNESVBHWVc2OHZ4empuYlEwTDM4WkxDcDZVMDIxY2VyY015Y1cyWlhMMXlqWXFLT2ZwZHoxRDVmd0VESVZqRUd4UkE2T204TnF2eFBOYVp5SDdKV1hCSTJVSC00Y0tfdG9iUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BofA raises Arvinas stock price target on Veppanu out-licensing deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQMlFVc0NxNlhpNVI0YnQtelZnVGhfYWF1ZUk4bVpuajNlR1F4bk40aWJucWw3ZmoxWFZGMDhNRG5Sbm53MUh5LXBkTi1OQ0dNanpvZzlTdEQ1b0NhU2Ric0ZlbEh6VHNPVDlZZ2hPTEFHRlVva0JwekpuVmpLRGE4Q0NvblNWcHlwV21jcFN6eFFMSUdQSnVfYl9sY1BxeWtwazhqNy15SUY4bndxbDFOT3RJd3JuZEM0c1prWW5QbndEYXZjeUE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) Q1 Loss Of US$0.90 Per Share Challenges Bullish Margin Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas stock gains after Rigel deal for VEPPANU rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbjZ6elZPbkNoMjBDMjlhSkpGOWNLbnVXbVZtNDJ6SFNUUVF2NTF3Sml2THNTdU15WWdtejkwUkZkd1o5am1oeGRpdzN3Mmx2Vmh3cUxPTmFJd0hVVk1rM3llSGhBX2xLZWVRbjVBZHBlSmpUYUZfVVpodElhS3RZSHF2b2ZvYktOeVFKNFBTTkgwT0RwQnlTel9jeWtndjVtOG5OS1c2TWY4c3ZSRkxsYlo4bVdISjBR?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeE9ick5FRTVoV3JNRWtDbnluT2xFNTZSdERTU1l3NUhkT1MwaWEwZ3lGaHZveWdoSGc1cmswZXBoMm53TFY2OTU5ajBWX1FfSFdUdWY1UWRGMW1xVGlfU0dGTkdqcE9pM1dob2FwVGpucWpfdnJtajFXOVJOYXlhUUp6N2Rmd2VjY1RSbVUtMUZ3SDAtQTkzOHB0Sk9sVUlRbGgxY0tEMmVNOXF5VzRwYUhTY0dVUQ?oc=5", "source_name": "Reuters", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Arvinas (NASDAQ:ARVN) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOS0Z5amF4ZXFUT1lxaE1MblphTXNVbkhZQkFSMzFMdTFrclpFQVdRS25uWGhIeFVfSTROb0pFUlVmOEdMVWpwb3BLNUpQdFgzZTJfcFNDLVJxZFhlc1hRSFRYM2pqMEVzbUlFOGxZUVpINXhoTG12SUxfbTBxTEhfTEpPbUpVaUl1ZXNTOURicVZOa2xhRjJVMjg5UWk2WVVBUlpOVnNMMFZPNG8?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer drug VEPPANU shifts to Rigel in $85M Arvinas-Pfizer deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEZEeEw3bF9WMjhZRWZlWGVFMHFVWEtSSGcyUm9GaTQ2SmZMWkwtU2pDWDBzRVdWbVE2QVF5NTZFdFVBN3ZReTBPZ2szRmhFWThDcmR0RHNoQzE1U0Rwc3JfSkxkWTctcU9UR3JHeHJwc2dDamxUeVVzZ0w2S1o4bVd0dTAxZVBzQ05UTm9vWUxoSFc0UlpFMFRvVjJsMHNXbTdoeTNQZkdYRXlJWnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNUlBKZVJXSE15Y3NsanZ2MVo2NGZsUXRJZ2RYSFptVE9CUTJWbVRybm1IYWxMMTNBUmp1NHR3emhBU3EwUW96VmJEdW1kU1lGUXlOZHRMUEROMkRXc3NFcHBOcVJ0WUo3U21IRlhIRGlZUE1FajYySi1tYXhuTF83bGl0ZWdxREk1NjZIaHFUNXdMSXVnaEdv?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Arvinas says on May 12: Q1 results and corporate update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVnpuNU1ORVJsNWRVcmt0WE0yazNyaEVjR2tpQk42YmNJX0txanlBZkR4UjNudXl5NWIwVXVBZHk2QzBrV0hJQ2xlQ3FNQkNhQUxOVXRtRVBNd3p0eHhhX1JjWWI3ODFJTW45SGNrYUtUV192UjlpNExNanRYNlZUa0tYM0FHanpPN1EtWlE5WGkySEN2T0VUZzhMaWFXZ1YwVkJOWlBjd0hNWXRTOUpEN29xYi13UUtpZkFv?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOaXlFMXRUWGRiWXNfRmdfdk9LRXRhZ08yZkhaNnRkTFVsak8wbG9NUE40WUhfZ0Z1MnZQZzFIdFZFcmhsUDBXU2RMdm1jT1ZNN2plV21lenhoNFRYOVdKclRLRzFJa2p5MHljUUhwekU1WHQyN0FmNnFhVGRlQ1hhd3hEa3Rpakw4TmVtREhja1hWcFhnb2lGeF9KVnFGcFNw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Trading the Move, Not the Narrative: (ARVN) Edition", "summary": "This article analyzes Arvinas Inc. (NASDAQ: ARVN) using AI models to provide trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but long-term strength, with specific entry, target, and stop-loss levels for position trad", "url": "https://news.stocktradersdaily.com/news_release/39/Trading_the_Move,_Not_the_Narrative:_ARVN_Edition_071726053402_1784280842.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T05:34:06", "published_display": "17 Jul 2026 05:34", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AJBVV95cUxQX2R4b2NwclZnek9PbWp0bV8wYzhmbTd6Ym9CZTFnMVZiU1ZEREJLWEtNTEdYdmtfamJrVkphQS1QZjZrNE5ESlpNS0hmd2xjSHNGUkZhMDBiN3QtYjNvOG1QQWZZQ1NiNDVTVjBXYk9YbzBzWUZFdHIzQjliU0tYbHQ0QlBOMlJQcU1nRW9wdnVNUGFGcjRnQ1NoSGlEYnU3U0MyLV9ZWGcwdWs1UElLRVdadTJRbmV5UGp4NTd3bW1ZaHhDWjlDR2p4cEZfY0cySzNTS0xUMUR1aW1pVS1QcXhxdjdiSVpkaTlUZGJ3Q29YWUtfSEt3WUNxNThqeExXbWNhd3FRWHIwRHBkSE1SWGdkUmVud1V5T193WUU4T0FpSXBlZ0t5dVc5b1dXckpoaVNOck9oZ2Q2RXB5cDBFZGRORmFpWThLLW9lZlRjNGhpeG54ajdIZ0xLNDE5eU9Q?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T20:32:37+00:00", "published_display": "13 Jul 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN News | ARVINAS INC (NASDAQ:ARVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5wNTZ4VGhRWXk2TTBaQUZvVk84YlBWcHFEWU5QeXNuWmFhcmprREcwSzN1QzNjWmMzeGFOOG91NG1seWVFdlVoR1RBTTVOT09QVnVTbW9YazNJWkE?oc=5", "source_name": "ChartMill", "published_at": "2026-07-10T21:48:26+00:00", "published_display": "10 Jul 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares", "summary": "Morgan Stanley Smith Barney LLC has filed a Form 144 notice indicating its intent to sell 24,000 shares of common stock in Arvinas, Inc. (ARVN). These sales are tied to restricted stock vesting under a registered plan, with specific vesting lots scheduled for March 2025, February", "url": "https://www.stocktitan.net/sec-filings/ARVN/144-arvinas-inc-sec-filing-1af59be62526.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:41:52", "published_display": "09 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN - Arvinas Inc Latest SEC Filings", "summary": "This article provides a detailed financial overview and recent SEC filing information for Arvinas Inc. (ARVN). It covers various financial metrics including market capitalization, sales, income, profitability ratios, insider and institutional ownership, stock performance, and ana", "url": "https://finviz.com/stock?t=ARVN&p=d&b=2&r=m3&ty=lf&page=9", "source_name": "Finviz", "published_at": "2026-07-03T10:10:15", "published_display": "03 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) director receives RSU and stock option grants in equity award", "summary": "Arvinas (ARVN) director Leslie V. Norwalk received routine equity compensation through a grant of 15,527 restricted stock units (RSUs) and an option to purchase 22,714 shares of common stock at $8.05 per share. These awards, granted on June 24, 2026, are not open-market trades an", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-5e63b48ea57d.html", "source_name": "Stock Titan", "published_at": "2026-06-27T08:10:24", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arvinas Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Arvinas Inc. on June 26. The content includes market data for various indices, currencies, and commodities, reflecting market performance. It also lists trending stocks and popular articles related to financial ne", "url": "https://za.investing.com/news/stock-market-news/form-4-arvinas-inc-for-26-june-93CH-4346330", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T22:26:00", "published_display": "26 Jun 2026 22:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options", "summary": "Arvinas (ARVN) director Briggs Morrison was granted 15,527 restricted stock units (RSUs) and 22,714 stock options with an exercise price of $8.05 per share. These equity awards, reported on a Form 4 filing, are subject to vesting criteria tied to continued service and the company", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-66a021c4281a.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:41:20", "published_display": "26 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Linda Bain receives RSUs and stock options at Arvinas (ARVN)", "summary": "Arvinas, Inc. director Linda Bain was granted 15,527 restricted stock units (RSUs) and stock options for 22,714 shares at an exercise price of $8.05 per share. Both the RSUs and options vest fully on the earlier of June 24, 2027, or immediately before the first annual stockholder", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-497040da74a1.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:41:20", "published_display": "26 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] ARVINAS, INC. Insider Trading Activity", "summary": "Edward M. Kennedy Jr., a director at ARVINAS, INC. (ARVN), received new equity awards comprising 15,527 restricted stock units (RSUs) and an option to purchase 22,714 shares at an exercise price of $8.05 per share. These awards were granted on June 24, 2026, and are set to vest f", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-bf718e269e1c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:41:20", "published_display": "26 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) director receives new RSU and stock option awards", "summary": "Arvinas, Inc. director Everett Cunningham was granted 15,527 restricted stock units (RSUs) and a stock option for 22,714 shares at an exercise price of $8.05, according to a June 24, 2026 filing. Both awards are set to vest on the earlier of June 24, 2027, or immediately before t", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-5f8750cdc6da.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:37:35", "published_display": "26 Jun 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSUNNUjAydlN2ZXJKMXdDZV8taDJZNzMxRUVVbm5fV3RrelNkYXRfazJ2c2JCZWZiQ21BcWh3dFRDd1FwNmxnckw2SlJNYXZ4SlhQWlYzZDZ5RFpERzBpODBENmZiYktfM0FTbklELW9xcEpmcHFKZ1RvZ2s5X3p6LW1GTlV0M1RqeUNYanlZS0VaUGZ1SjZjX1pxM0JTNlVvZHk3RERyMjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN)", "summary": "This article provides key financial actuals and estimates for Arvinas, Inc. (NASDAQ:ARVN), including its current stock price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent earnings, revenue, net income, and upcoming earnings repor", "url": "https://www.tradingview.com/symbols/NASDAQ-ARVN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:20", "published_display": "26 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Inc (ARVN) Institutional Confidence", "summary": "Arvinas Inc (ARVN) has an institutional shareholding score of 7.00, placing it 80th out of 387 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 83.59%, which is a decrease of 50.35% quarter-over-quarter. Bill Nygren | OAKMX is the lar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arvn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-26T04:40:21", "published_display": "26 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor", "summary": "Arvinas, Inc. held its annual meeting on June 24, 2026, where stockholders elected Leslie V. Norwalk, Esq. and Randy Teel, Ph.D. as Class II directors. They also approved, on a non-binding advisory basis, the compensation for named executive officers and ratified Deloitte & Touch", "url": "https://www.stocktitan.net/sec-filings/ARVN/8-k-arvinas-inc-reports-material-event-023a4cb3428e.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:40:08", "published_display": "25 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas CFO Andrew Saik sells $46,473 in company stock", "summary": "Arvinas CFO Andrew Saik sold 5,696 shares of company stock for $46,473 to cover tax withholding obligations related to the vesting of restricted stock units. This was not a discretionary trade. The stock is currently trading below its fair value, despite a recent earnings report ", "url": "https://www.investing.com/news/insider-trading-news/arvinas-cfo-andrew-saik-sells-46473-in-company-stock-93CH-4759239", "source_name": "Investing.com", "published_at": "2026-06-25T20:09:35", "published_display": "25 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arvinas Inc For: 24 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Arvinas Inc (ARVN) dated June 24, 2026. Form 4s disclose transactions by company insiders, but the article provides no specific details about the transactions, only listing the filing and referencing the stock ticker.", "url": "https://ng.investing.com/news/stock-market-news/form-4-arvinas-inc-for-24-june-93CH-2573010", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T19:37:35", "published_display": "25 Jun 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Arvinas, Inc. (ARVN) stock, including analyst price targets, current stock performance, and financial data. It highlights that the stock has a price target of 15.07 USD based on 14 analysts, with a max estimate of 24.00 USD and a min of 6.00 U", "url": "https://www.tradingview.com/symbols/NASDAQ-ARVN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:21", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVINAS (ARVN) CFO auto-sells shares to cover RSU tax withholding", "summary": "ARVINAS, INC.'s Chief Financial Officer, Andrew Saik, automatically sold 5,696 shares of common stock at $8.159 per share to cover tax withholding obligations related to the vesting of his restricted stock units. This was a non-discretionary sale made by the company and not a per", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-a8fa1bc4f627.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:10:13", "published_display": "24 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Arvinas Inc For: 23 June By Investing.com", "summary": "This article from Investing.com reports on Form 144 for Arvinas Inc. filed on June 23rd. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the filing date and company name.", "url": "https://ng.investing.com/news/stock-market-news/form-144-arvinas-inc-for-23-june-93CH-2571125", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T18:11:29", "published_display": "24 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARVN: All voting items passed at the virtual meeting, with no shareholder questions submitted", "summary": "Arvinas, Inc. (ARVN) held its virtual Annual General Meeting (AGM) where all proposed agenda items were approved by shareholders. These items included director elections, executive compensation, and auditor ratification. No shareholder questions were submitted during the meeting.", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3648079:0-arvn-all-voting-items-passed-at-the-virtual-meeting-with-no-shareholder-questions-submitted/", "source_name": "TradingView", "published_at": "2026-06-24T13:41:25", "published_display": "24 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) to settle 5,846 vested RSU shares on 06/24/2026", "summary": "Arvinas, Inc. (NASDAQ: ARVN) is set to settle 5,846 shares of common stock stemming from vested restricted stock units on June 24, 2026, through Morgan Stanley Smith Barney LLC. The SEC Form 144 filing also notes a previous disposition of 11,139 shares by Andrew Saik on May 11, 2", "url": "https://www.stocktitan.net/sec-filings/ARVN/144-arvinas-inc-sec-filing-50c29b2381fd.html", "source_name": "Stock Titan", "published_at": "2026-06-23T21:40:40", "published_display": "23 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] ARVINAS, INC. Reports Material Event", "summary": "ARVINAS, INC. has reported a material event in an 8-K filing, announcing that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. will depart from the company on July 3, 2026. A separation agreement includes nine months of base salary, health premiums, and accelerated vesting of ce", "url": "https://www.stocktitan.net/sec-filings/ARVN/8-k-arvinas-inc-reports-material-event-e64329957ef4.html", "source_name": "Stock Titan", "published_at": "2026-06-23T05:40:40", "published_display": "23 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas, Inc. $ARVN Stock Holdings Lifted by Armistice Capital LLC", "summary": "Armistice Capital LLC significantly increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 50% in the fourth quarter, now holding 1.8 million shares valued at $21.35 million. While institutional investors are increasing positions, company insiders, including the CFO, recently sold", "url": "https://www.marketbeat.com/instant-alerts/filing-arvinas-inc-arvn-stock-holdings-lifted-by-armistice-capital-llc-2026-06-18/", "source_name": "MarketBeat", "published_at": "2026-06-19T22:09:24", "published_display": "19 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) CSO has shares sold automatically to cover RSU tax withholding", "summary": "Arvinas, Inc.'s Chief Scientific Officer, Angela M. Cacace, automatically sold 2,576 shares of common stock at $7.595 per share. This non-discretionary sale was executed by the issuer to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). ", "url": "https://www.stocktitan.net/sec-filings/ARVN/form-4-arvinas-inc-insider-trading-activity-05b684d2b303.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:43:39", "published_display": "18 Jun 2026 19:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment", "summary": "Rigel Pharmaceuticals has secured exclusive global rights to develop and commercialize VEPPANU from Arvinas and Pfizer, following the early termination of the Hart-Scott-Rodino waiting period. This agreement triggered an upfront payment of $70 million, shared by Arvinas and Pfize", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARVN/pressreleases/2525021/rigel-deal-for-veppanu-cleared-arvinas-receives-payment/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T05:40:40", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Arvinas Inc (ARVN) has an earnings forecast score of 7.40, ranking 293 out of 388 in the Biotechnology & Medical Research industry. The average analyst price target for ARVN is $14.00, with 18 analysts predominantly recommending a \"Buy\" trend. The company's expected revenue for t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arvn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:48", "published_display": "17 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Inc (ARVN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of Arvinas Inc's (ARVN) dividend payouts and stock splits, noting that the company has distributed $0.00 in dividends over the past five years. It also indicates that there is no historical data available for stock splits. The content pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arvn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:36", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) insider sells 2,642 shares; May sale of 9,657 noted", "summary": "An insider at Arvinas (NASDAQ: ARVN) sold 2,642 shares on June 17, 2026, stemming from vested restricted stock units. This Form 144 SEC filing also notes a previous sale of 9,657 common shares by Angela Cacace on May 11, 2026, for $95,965.47. The transactions are considered routi", "url": "https://www.stocktitan.net/sec-filings/ARVN/144-arvinas-inc-sec-filing-ab03911b86fb.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:10:23", "published_display": "17 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a", "summary": "An agreement between Arvinas Holding Company LLC and Pfizer, detailed in a U.S. SEC document, outlines potential milestone payments of up to $320 million and a tiered royalty structure for both companies. These payments are phased based on R&D progress, regulatory approvals, and ", "url": "https://www.bitget.com/amp/news/detail/12560605463269", "source_name": "Bitget", "published_at": "2026-06-16T21:40:00", "published_display": "16 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (NASDAQ: ARVN) secures $70M VEPPANU payment and major milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQcUZKWVkyQlZ6emdlVGgybkJDMEdMU0VIWDQ0U2lTdFpLZHBhMm5PTDdhQjJtX2tpeDF2OERaRnJrTnoxS3dCb2hZYzEzcDdXUzFmeDVPWDN4aWdEX0FUTzMzZ1MtLVhLOUNGTEl4YnljQ3pudUZUSE91eXBZYkthMzNIQlJrZ3lFTDFjczR4UmRoMTZPMDQxaGRCQThzTmZtNGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data", "summary": "", "url": "https://finance.yahoo.com/m/09445a3d-4d83-38f8-9d7f-b4d836f150fd/arvinas-sharpens-pipeline.html", "source_name": "MarketBeat", "published_at": "2026-06-05T16:10:37+00:00", "published_display": "05 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Joins The Michael J. Fox Foundation\u2019s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arvinas-joins-michael-j-fox-120000666.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas joins Michael J. Fox effort to develop new Parkinson's therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQQnBZM0p5ZnpQRUVnWlRmdWdxV3FOQ2RZX1hiUndtT3RkVEREVW1QY3Z1SUJDWF9zeFN6ZFRkZzVoN2dvT1lObWpqaVZjajhXSS1aSHhXcUlVRmc5RUdRUlVyV3NHazlPT0dLV3BfU0Z3ZHR5Zkl2SHdNd1JaMEVYbUtZdGZPSjR2Q1RVNmswODgzbUZWOE5teXdtdGw4R3MxcEh4QTVjakFZeHptSWxNTXV3ZlItNnV3NGNybmRQQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas to Present at Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arvinas-present-jefferies-global-healthcare-200100166.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T20:01:00+00:00", "published_display": "29 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies healthcare conference to feature Arvinas fireside chat June 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPZnppbFl4T3NuUkNrckRmUGw5eUREaXkxaEtveDUyWTdOQllvTkcyLUFfdVJHa0RUN1F2WkwySEwzWWVkMllhSlBaY0M5QkwtcjB0WkpUT3o1NjRqZDFMSzk1MjNkXzU3bmp5Z01lZzNJU25Mem5CQmt2dUE1MmlmWGNDa2pMMl9XTm14enBoa0pGWlhVZllCWnpXQTlwdllCTU1HTnFkUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas Employees Give Back During Company-wide Impact Day", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arvinas-employees-back-during-company-143000094.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T14:30:00+00:00", "published_display": "18 May 2026 14:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas staff spend a day cooking, cleaning and crafting for patients and kids", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQWk5leXN0UXBoamlsUHA4YmtsaUExYi1iN1JGaGwxSVR4UFBXelhkcGJRY2pQVDlneWZnNktKcVBuWlB5eEx6Z3RhcWYtaFUxcFdLNnVuMGdrV1k0TnB0MFRyVWUyRHFVRkE0ZUt5Y0tHZjBROWhlTXE1TVVNS2E0U0NkZFFPR1d4dG9BYzVpMkc4bFVMMER4RWxGUnBISkcxWTZjSnRGWkZTNWJGZ2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bullish-analysts-just-made-noticeable-134017950.html", "source_name": "Simply Wall St.", "published_at": "2026-05-16T13:40:17+00:00", "published_display": "16 May 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rigel-pharmaceuticals-inks-breast-cancer-203107776.html", "source_name": "Benzinga", "published_at": "2026-05-15T20:31:07+00:00", "published_display": "15 May 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNRkxVR2xZM1lqdGZ2NXh2Qk1VYkwzazNLUEc4TGFVVlhUaU9VTEhyX3didlBnWFBzVVhvcDNESVBHWVc2OHZ4empuYlEwTDM4WkxDcDZVMDIxY2VyY015Y1cyWlhMMXlqWXFLT2ZwZHoxRDVmd0VESVZqRUd4UkE2T204TnF2eFBOYVp5SDdKV1hCSTJVSC00Y0tfdG9iUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA raises Arvinas stock price target on Veppanu out-licensing deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQMlFVc0NxNlhpNVI0YnQtelZnVGhfYWF1ZUk4bVpuajNlR1F4bk40aWJucWw3ZmoxWFZGMDhNRG5Sbm53MUh5LXBkTi1OQ0dNanpvZzlTdEQ1b0NhU2Ric0ZlbEh6VHNPVDlZZ2hPTEFHRlVva0JwekpuVmpLRGE4Q0NvblNWcHlwV21jcFN6eFFMSUdQSnVfYl9sY1BxeWtwazhqNy15SUY4bndxbDFOT3RJd3JuZEM0c1prWW5QbndEYXZjeUE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas (ARVN) Q1 Loss Of US$0.90 Per Share Challenges Bullish Margin Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas stock gains after Rigel deal for VEPPANU rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbjZ6elZPbkNoMjBDMjlhSkpGOWNLbnVXbVZtNDJ6SFNUUVF2NTF3Sml2THNTdU15WWdtejkwUkZkd1o5am1oeGRpdzN3Mmx2Vmh3cUxPTmFJd0hVVk1rM3llSGhBX2xLZWVRbjVBZHBlSmpUYUZfVVpodElhS3RZSHF2b2ZvYktOeVFKNFBTTkgwT0RwQnlTel9jeWtndjVtOG5OS1c2TWY4c3ZSRkxsYlo4bVdISjBR?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeE9ick5FRTVoV3JNRWtDbnluT2xFNTZSdERTU1l3NUhkT1MwaWEwZ3lGaHZveWdoSGc1cmswZXBoMm53TFY2OTU5ajBWX1FfSFdUdWY1UWRGMW1xVGlfU0dGTkdqcE9pM1dob2FwVGpucWpfdnJtajFXOVJOYXlhUUp6N2Rmd2VjY1RSbVUtMUZ3SDAtQTkzOHB0Sk9sVUlRbGgxY0tEMmVNOXF5VzRwYUhTY0dVUQ?oc=5", "source_name": "Reuters", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Arvinas (NASDAQ:ARVN) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOS0Z5amF4ZXFUT1lxaE1MblphTXNVbkhZQkFSMzFMdTFrclpFQVdRS25uWGhIeFVfSTROb0pFUlVmOEdMVWpwb3BLNUpQdFgzZTJfcFNDLVJxZFhlc1hRSFRYM2pqMEVzbUlFOGxZUVpINXhoTG12SUxfbTBxTEhfTEpPbUpVaUl1ZXNTOURicVZOa2xhRjJVMjg5UWk2WVVBUlpOVnNMMFZPNG8?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer drug VEPPANU shifts to Rigel in $85M Arvinas-Pfizer deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEZEeEw3bF9WMjhZRWZlWGVFMHFVWEtSSGcyUm9GaTQ2SmZMWkwtU2pDWDBzRVdWbVE2QVF5NTZFdFVBN3ZReTBPZ2szRmhFWThDcmR0RHNoQzE1U0Rwc3JfSkxkWTctcU9UR3JHeHJwc2dDamxUeVVzZ0w2S1o4bVd0dTAxZVBzQ05UTm9vWUxoSFc0UlpFMFRvVjJsMHNXbTdoeTNQZkdYRXlJWnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNUlBKZVJXSE15Y3NsanZ2MVo2NGZsUXRJZ2RYSFptVE9CUTJWbVRybm1IYWxMMTNBUmp1NHR3emhBU3EwUW96VmJEdW1kU1lGUXlOZHRMUEROMkRXc3NFcHBOcVJ0WUo3U21IRlhIRGlZUE1FajYySi1tYXhuTF83bGl0ZWdxREk1NjZIaHFUNXdMSXVnaEdv?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Arvinas says on May 12: Q1 results and corporate update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVnpuNU1ORVJsNWRVcmt0WE0yazNyaEVjR2tpQk42YmNJX0txanlBZkR4UjNudXl5NWIwVXVBZHk2QzBrV0hJQ2xlQ3FNQkNhQUxOVXRtRVBNd3p0eHhhX1JjWWI3ODFJTW45SGNrYUtUV192UjlpNExNanRYNlZUa0tYM0FHanpPN1EtWlE5WGkySEN2T0VUZzhMaWFXZ1YwVkJOWlBjd0hNWXRTOUpEN29xYi13UUtpZkFv?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOaXlFMXRUWGRiWXNfRmdfdk9LRXRhZ08yZkhaNnRkTFVsak8wbG9NUE40WUhfZ0Z1MnZQZzFIdFZFcmhsUDBXU2RMdm1jT1ZNN2plV21lenhoNFRYOVdKclRLRzFJa2p5MHljUUhwekU1WHQyN0FmNnFhVGRlQ1hhd3hEa3Rpakw4TmVtREhja1hWcFhnb2lGeF9KVnFGcFNw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 62, "sentiment_summary": {"positive": 9, "negative": 5, "neutral": 48, "score": 51, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 3.1, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 8.27, "latest_week": "2026-07-10", "one_week_move": -1.4, "four_week_move": 9.1, "twelve_week_move": -24.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.445938, "market_dynamics_buy_signal": false, "relative_strength": -29.641339, "fair_value_gap": -57.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 50.3809, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.4% over one week, +9.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 19}, {"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 5}, {"label": "TradingView", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.4% over one week, +9.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Trading the Move, Not the Narrative: (ARVN) Edition"}], "updated_at": "2026-07-18T02:05:36.814585+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}